Search Bar & Filters
Found 7 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating etavopivat, a new oral medicine being developed for blood disorders such as sickle cell disease and thalassaemia. These inherited conditions affect hemoglobin, the protein responsible for carrying oxygen in the body. This long-term study aims to assess the safety and effectiveness of etavopivat treatment over a period of up to 264 weeks, or until the drug is approved in the participants country. Participants will receive one of several oral doses of etavopivat, with dosing adjusted by age those 12 years and older will receive Etavopivat A or C, while children younger than 12 years will receive Etavopivat B. The study involves multiple groups including adults, adolescents, and children with different types of sickle cell disease or thalassaemia. All participants have completed a prior etavopivat treatment study and are continuing treatment in this rollover study. During the study, participants will be regularly monitored for treatment-related side effects and clinical benefits. Researchers will track adverse events, blood crisis rates, hemoglobin levels, hospitalizations, and blood transfusion needs. The study includes long-term safety and efficacy assessments conducted over several years, with monitoring continuing until study completion or drug approval. Participants health and treatment responses will be carefully followed throughout this extended period.
Actively Recruiting
Researchers are studying the daily use of Rifapentine combined with Isoniazid to prevent tuberculosis in children under 13 years old, including those with and without HIV. This Phase III trial aims to find the appropriate dose of this combination taken once daily for 28 days. The study will include up to 144 children divided into two groups based on HIV status and will take place at multiple locations. Participants will receive the study drugs by oral dispersible tablets, grouped by weight into five categories. Children with HIV will also be assessed for their use of Dolutegravir as part of their antiretroviral therapy. The treatment period lasts 28 days, followed by a 24-week follow-up to monitor safety, tolerability, and drug levels in the blood. Both groups will be closely observed to assess how the drugs are processed in their bodies and any adverse effects. During the study, participants will have blood tests to measure drug concentrations and monitor liver, kidney, and blood cell function. Parent or guardian reports on treatment acceptability and adherence will be collected. Researchers will track adverse events throughout the treatment and follow-up periods. The total participation duration includes the initial 28-day dosing phase and subsequent 24 weeks of monitoring to ensure safety and effectiveness of the regimen.
Actively Recruiting
Researchers are evaluating the pharmacokinetics and safety of etavopivat in children with sickle cell disease SCD. The study involves pediatric participants ranging in age from 6 months to less than 18 years and is designed as a phase 2, open-label, single-group study. Participants will be enrolled in age-based cohorts starting with the oldest group, with younger groups added sequentially after reviewing safety and pharmacokinetic data from prior cohorts. Participants will receive oral etavopivat once daily as either tablets or granules. The treatment includes a primary period lasting 24 weeks, followed by a 72-week extension period to further assess long-term safety and pharmacokinetics. The total study duration for each participant is approximately 96 weeks. Four age cohorts are studied 12 to less than 18 years, 6 to less than 12 years, 2 to less than 6 years, and 6 months to less than 2 years. Throughout the study, participants will be closely monitored with blood tests measuring etavopivat levels and hemoglobin changes, assessments of vaso-occlusive crisis frequency, and fatigue scales. Safety is evaluated by tracking adverse events, dose changes, and treatment interruptions. Transcranial Doppler ultrasound is used to assess cerebral blood flow at scheduled visits. The study includes frequent evaluations during both treatment periods to understand the drugs effects and safety in this young population.
Actively Recruiting
Researchers are conducting an observational study called the Multinational Observational Cohort of HIV and Other Infections MOCHI to understand the number of new HIV infections among people vulnerable to acquiring HIV. This study is carried out across multiple international sites and focuses on individuals aged 14 to 55 years who engage in behaviors that increase their risk of HIV. It aims to gather information on HIV incidence as well as other sexually transmitted infections STIs. The study is divided into two steps. Step 1 enrolls participants aged 14 to 55 years who are vulnerable to HIV and evaluates them every 12 weeks for HIV and other STIs. Participants diagnosed with HIV in Step 1 move to Step 2, where they receive more frequent evaluations including viral load and other HIV-related tests every four weeks for 12 weeks, then every 12 weeks, with a total follow-up of 48 weeks in Step 2. Participants will attend regular visits for testing and evaluation throughout the study period. In Step 1, evaluations occur every 12 weeks, while in Step 2, participants have more frequent visits for detailed monitoring of their HIV status and viral load. Researchers will measure HIV incidence, STI prevalence, and willingness to participate over a 10-year period. The study includes collecting information on risk behaviors and monitoring participants health through laboratory tests and questionnaires.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety and pharmacokinetics of two powerful, broadly neutralizing anti-HIV monoclonal antibodies called PGT121.414.LS and VRC07-523LS in infants exposed to HIV-1. This open-label, phase I study focuses on administering these antibodies soon after birth to understand their behavior and safety in this vulnerable population. Participants receive one or two subcutaneous doses of PGT121.414.LS alone or combined with VRC07-523LS. The first dose is given at birth based on the infants weight. For some groups, a second dose is administered at Week 12 if the infant is still breastfeeding. The study evaluates the antibody levels and safety through Week 12 for one dose and through Week 24 for two doses. During the study, infants undergo regular safety assessments and blood tests to monitor antibody levels and adverse events. Researchers measure the occurrence of significant side effects, antibody concentrations, and the infants HIV status through Week 96. The study includes monitoring injection site reactions and immune responses to the antibodies, with the total participation lasting up to about two years.
Actively Recruiting
This research aims to compare a six-month treatment plan using higher doses of rifampicin, isoniazid, linezolid, and pyrazinamide with the World Health Organizations standard nine-month treatment for tuberculous meningitis TBM in adults and adolescents. Tuberculous meningitis is a serious condition with high risk of death and severe neurological problems. This Phase II, randomized, open-label trial seeks to evaluate if the shorter high-dose regimen can improve functional outcomes compared to the standard care.
Actively Recruiting
Researchers are studying the effects of early intensive antiretroviral therapy ART with or without broadly neutralizing antibodies on achieving HIV remission in infants living with HIV. This phase III study includes two groups infants born to mothers with limited or no antiretroviral use during pregnancy and infants diagnosed with HIV within 48 hours of birth who start ART immediately. The goal is to see if early treatment can suppress HIV to undetectable levels. Participants will receive one of seven intensive ART regimens combining nucleoside reverse transcriptase inhibitors NRTIs with drugs like nevirapine, lopinavirritonavir, raltegravir, dolutegravir, and monoclonal antibodies VRC01 or VRC07-523LS. Therapy begins within 48 hours of birth and may include switches in medication based on age and weight. The study has four steps initial evaluation and therapy start, up to 192 weeks of treatment with monitoring, possible treatment interruption for those with sustained viral suppression, and re-initiation of ART if viral rebound occurs. During the study, infants undergo regular HIV testing, safety monitoring, and immune assessments. Researchers track how many achieve HIV remission by week 48 and monitor viral suppression and adverse events through week 192. If treatment interruption is attempted, participants are closely observed for viral rebound for up to ten years, followed by monitoring after ART re-initiation until age five or six months after viral suppression. The entire study may last several years to evaluate long-term outcomes.